Navigation Links
Perrigo Confirms Filing for Generic Version of Gynazole-1® Cream and Announcement of Patent Infringement Lawsuit by KV Pharma
Date:7/30/2010

ALLEGAN, Mich., July 30 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO;TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for butoconazole nitrate vaginal cream, 2% and that is has notified KV Pharmaceutical Company, the owner of the New Drug Application (NDA) as well as FemmePharma, the listed owner of the patent, of its ANDA filing. KV is a licensee under the patent.  Perrigo believes it is first-to-file on this product.

On July 29, 2010, KV Pharmaceutical Company filed suit in the United States District Court for the District of Delaware, alleging patent infringement to prevent Perrigo from proceeding with the commercialization of this product. This action formally initiates the process under the Hatch-Waxman Act.  The suit also named FemmePharma as a defendant as it had not agreed to join KV as a plaintiff in the suit.

Gynazole·1® (butoconazole nitrate) vaginal cream, 2% is indicated for the local treatment of vulvovaginal candidiasis (infections cause by Candida).  Prior to its being discontinued in January 2009 due to manufacturing issues at KV, its annual sales were approximately $28 million annually, as measured by Wolters Kluwer Health.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing is another example of our investment in new products and expansion of our product portfolio. The first to file status also reflects Perrigo's continued focus on being first to market with new products. As always, Perrigo is committed to making quality healthcare more affordable for our cu
'/>"/>

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015  Amgen (NASDAQ: AMGN ... termination of its participation in the co-development ... STO:AZN and NYSE: AZN ).  Brodalumab, ... for patients with moderate-to-severe plaque psoriasis, psoriatic ... based on events of suicidal ideation and ...
(Date:5/22/2015)... , May 22, 2015  BioLife Solutions, Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and cryopreservation ... for cells and tissues ("BioLife" or the "Company"), announced that ... MicroCap Conference. The Company is scheduled to ... May 27, 2015 at the Grand Hyatt Hotel in ...
(Date:5/22/2015)... May 22, 2015 The North American ... and is estimated to reach $90.7 million by 2019, at ... Browse through the TOC of North America Dental Lasers Market ... help of various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... on this report.   Dental lasers are ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3
... new analysis,presented today from METEOR (Measuring Effects on ... (rosuvastatin calcium) 40,mg slowed the progression of carotid ... levels of risk for cardiovascular disease.,The sub- study ... risk,assessment tool as having less than two or ...
... ORLANDO, Fla., Nov. 7 Astellas Pharma US, ... conversion to normal heart rhythm (sinus rhythm, or ... artery bypass,graft (CABG) or valvular surgeries. AF is ... rhythm and a high heart rate. The study,results ...
Cached Medicine Technology:New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 2New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 4New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 5New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 6Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery 2Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery 3
(Date:5/25/2015)... A recent report for Mass Live made ... a direct result of an opiate overdose in the state ... overdose deaths attributed to prescription opiate medications, and heroin. Mass ... geography. This issue doesn’t care about race. This issue doesn’t ... the state of Mass. reels from the effects of the ...
(Date:5/25/2015)... CA (PRWEB) May 25, 2015 Join Fiona's ... a free two-hour instructional clinic. Irish National Player, Fiona ... and give them a taste of her coaching style. Fiona ... and Novato. Camps in Novato are at Lynwood Elmentary School ... , Novato High School - June 6th, 2015 - 1:00-3:00pm. ...
(Date:5/25/2015)... TX (PRWEB) May 25, 2015 Decora Preset ... company ‘Leviton’ is now available on ‘The Hardware City.’ The ... user has to set a time and the related electronic ... When contacted a representative of the company said, “We are ... Hardware City.’ Now customers can buy Countdown Timer Switch in ...
(Date:5/24/2015)... May 24, 2015 For people who ... Chinese Enterokinase Industry, 2009-2019 Market Research Report would be ... an exhaustive study on the present market scenario of ... into the growing Chinese market of this industry. The ... overall status of the manufacturers in this industry. The ...
(Date:5/24/2015)... York (PRWEB) May 24, 2015 ... lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled its next ... of the multidistrict litigation. According to court documents ... of Illinois, the Conference will be convened on ... Testosterone Replacement Therapy Product Liability Litigation - MDL ...
Breaking Medicine News(10 mins):Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:US Sports Camps and Nike Soccer Camps Offer Complimentary Instructional Clinic with Fiona's Soccer Camp 2Health News:Leviton's Decora 60 Minute Countdown Timer Available On ‘The Hardware City’ 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3
... Patient Educational Program Urges Americans to ,Fight Against Heart ... ... Many U.S. adults are confused about,what heart failure is, cannot ... is a manageable condition, according,to a new survey conducted by Harris ...
... becomes newest reseller ... wireless microphone, MAYNARD, Mass., Feb. 12 ... enhancing collaboration, today announced,that the Dictaphone Healthcare Solutions ... Wireless Microphone alongside its Dragon(R),NaturallySpeaking(R) Medical speech recognition ...
... Video Blogs on,DeterminedToQuit.com, HARRISBURG, Pa., Feb. 12 ... to quit using tobacco are,now being featured on ... site, http://www.DeterminedToQuit.com ., Angela and Justin ... than a,year and are determined to quit smoking ...
... Organizations Support Wyeth Campaign to Eliminate Compounded ... International,Academy of Compounding Pharmacists (IACP) today called ... and the North American,Menopause Society (NAMS) to ... dispensing advice to patients and practitioners that ...
... Findings suggest some individuals or families may have underlying ... -- People with a personal or family history of ... rare type of dementia that causes them to lose ... report. , The condition, known as primary progressive ...
... PLANO, Texas, Feb. 12 With the recent announcement ... is an ongoing,safety review of Botox Cosmetic (botulinum toxin ... lines between the brows. Botox(R),Cosmetic received FDA approval in ... lines between the brows in people 18 to 65 ...
Cached Medicine News:Health News:New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment 2Health News:New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment 3Health News:New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment 4Health News:New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment 5Health News:New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment 6Health News:Revolabs xTag(TM) Wireless Microphone Now Offered as a Total Solution With Dragon(R) NaturallySpeaking(R) Medical Software from Nuance 2Health News:Revolabs xTag(TM) Wireless Microphone Now Offered as a Total Solution With Dragon(R) NaturallySpeaking(R) Medical Software from Nuance 3Health News:American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals 2Health News:Learning Disabilities May Presage Later Language Problems 2Health News:Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles 2
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... Products are constructed of a ... MEROCEL polyvinyl acetal sponge. Each ... beneficial to both surgeon and ... yet firm enough to gently ...
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
Medicine Products: